Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimensTamara Castaño-Bonilla, Pau Montesinos, Claudia Sargas et al.|Scientific Reports|2021Cited by 25
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA GroupTamara Castaño-Bonilla, Pau Montesinos, Eva Barragán et al.|Disease Markers|2022Cited by 2